Gene: CACNG2

10369
MRD10
calcium voltage-gated channel auxiliary subunit gamma 2
protein-coding
22q12.3
Ensembl:ENSG00000166862 MIM:602911 Vega:OTTHUMG00000030612 UniprotKB:Q9Y698
NG_031861.2
SNP Mapped
1   ANCO-SNPs
ND
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
4.168e-1 (AD)  7.330e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs6000351chr22:36614820 (GRCh38.p7)G>Anicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg18666630chr22:36963104CACNG2Gene body3.872e-4Alcohol use disorders26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MTUS20.942
GRIN2A0.936
SCN8A0.935
HECW10.926
NBEA0.924
TMEM178B0.922
LHFPL40.92
PLXNA40.919
LMTK20.919
GRIN2B0.918

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
RAB13-0.596
HEY2-0.581
ROM1-0.581
SNHG18-0.565
MYL3-0.557
YES1-0.556
COPZ2-0.55
S100A16-0.549
AGTRAP-0.545
RAI14-0.541

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00898EthanolSmall Molecule64-17-5ApprovedTarget
ID Drug Name Action PubMed
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of CACNG2 gene27153756
D000643Ammonium ChlorideAmmonium Chloride affects the expression of CACNG2 mRNA16483693
D001464BariumCACNG2 protein affects the transport of Barium11313431
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNG2 mRNA25607892
C006780bisphenol Abisphenol A results in decreased expression of CACNG2 mRNA25181051
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNG2 mRNA25607892
D002118CalciumCACNG2 protein affects the reaction [CACNA1G protein results in increased transport of Calcium]10734232
D002251Carbon TetrachlorideCarbon Tetrachloride results in decreased expression of CACNG2 mRNA16644059
D060729Coal AshCoal Ash results in increased expression of CACNG2 mRNA19000753
D003300Copper[Copper co-treated with Dietary Sucrose] results in increased expression of CACNG2 mRNA26033743
D003300CopperCopper deficiency results in increased expression of CACNG2 mRNA26033743
D003993Dibutyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CACNG2 mRNA25607892
D003633Dichlorodiphenyl Dichloroethylene[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CACNG2 mRNA25607892
D019422Dietary Sucrose[Copper co-treated with Dietary Sucrose] results in increased expression of CACNG2 mRNA26033743
D019422Dietary SucroseDietary Sucrose results in increased expression of CACNG2 mRNA26033743
D004051Diethylhexyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CACNG2 mRNA25607892
D004317DoxorubicinDoxorubicin affects the methylation of CACNG2 gene28962528
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNG2 mRNA25607892
C109476epoxiconazole[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CACNG2 mRNA25607892
D005419FlavonoidsFlavonoids results in decreased expression of CACNG2 mRNA18035473
C039281furanfuran results in decreased expression of CACNG2 mRNA26194646
D007649KetamineKetamine results in increased expression of CACNG2 mRNA20080153
D007854LeadLead affects the expression of CACNG2 mRNA28903495
D008044Linuron[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CACNG2 mRNA25607892
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of CACNG2 mRNA"20188158
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of CACNG2 mRNA"25926378
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNG2 mRNA25607892
D010936Plant ExtractsPlant Extracts results in decreased expression of CACNG2 mRNA23557933
C045362prochloraz[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CACNG2 mRNA25607892
C035988procymidone[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CACNG2 mRNA25607892
D011441PropylthiouracilPropylthiouracil results in decreased expression of CACNG2 mRNA24780913
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of CACNG2 mRNA25895662
D014241TrichloroethyleneTrichloroethylene results in increased methylation of CACNG2 gene27618143
C034028vanadyl sulfatevanadyl sulfate results in increased expression of CACNG2 mRNA16330358
C025643vinclozolin[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CACNG2 mRNA25607892

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005245voltage-gated calcium channel activity-IBA21873635  
GO:0005262calcium channel activity-TAS-  
GO:0005515protein binding-IPI20805473  
GO:0016247channel regulator activity-IBA21873635  
GO:0035255ionotropic glutamate receptor binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0007528neuromuscular junction development-IEA-  
GO:0019226transmission of nerve impulse-IBA21873635  
GO:0051899membrane depolarization-TAS-  
GO:0051968positive regulation of synaptic transmission, glutamatergic-IBA21873635  
GO:0060081membrane hyperpolarization-IEA-  
GO:0098943neurotransmitter receptor transport, postsynaptic endosome to lysosome-IBA21873635  
GO:0098943neurotransmitter receptor transport, postsynaptic endosome to lysosome-IEA-  
GO:0098970postsynaptic neurotransmitter receptor diffusion trapping-IBA21873635  
GO:0098970postsynaptic neurotransmitter receptor diffusion trapping-IEA-  
GO:0099590neurotransmitter receptor internalization-IBA21873635  
GO:0099590neurotransmitter receptor internalization-IEA-  
GO:2000311regulation of AMPA receptor activity-IBA21873635  
GO:2000311regulation of AMPA receptor activity-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-TAS-  
GO:0005891voltage-gated calcium channel complex-IEA-  
GO:0030054cell junction-IEA-  
GO:0030666endocytic vesicle membrane-TAS-  
GO:0032281AMPA glutamate receptor complex-IBA21873635  
GO:0032281AMPA glutamate receptor complex-ISS-  
GO:0036477somatodendritic compartment-IEA-  
GO:0043005neuron projection-IEA-  
GO:0098839postsynaptic density membrane-IBA21873635  
GO:0098839postsynaptic density membrane-IEA-  
KEGG ID KEGG Term
hsa04010MAPK signaling pathway
hsa04260Cardiac muscle contraction
hsa05410Hypertrophic cardiomyopathy (HCM)
hsa05412Arrhythmogenic right ventricular cardiomyopathy (ARVC)
hsa05414Dilated cardiomyopathy
Reactome ID Reactome Term Evidence
R-HSA-112308Presynaptic depolarization and calcium channel openingTAS
R-HSA-112314Neurotransmitter receptors and postsynaptic signal transmissionTAS
R-HSA-112315Transmission across Chemical SynapsesTAS
R-HSA-112316Neuronal SystemTAS
R-HSA-1266738Developmental BiologyTAS
R-HSA-397014Muscle contractionTAS
R-HSA-399719Trafficking of AMPA receptorsTAS
R-HSA-399721Glutamate binding, activation of AMPA receptors and synaptic plasticityTAS
R-HSA-5576891Cardiac conductionTAS
R-HSA-5576892Phase 0 - rapid depolarisationTAS
R-HSA-5576893Phase 2 - plateau phaseTAS
R-HSA-5682910LGI-ADAM interactionsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal